UBS Maintains Puma Biotechnology Inc to Buy with Price Target $60.00

Brokerage firm UBS Maintains its rating on Puma Biotechnology Inc(NYSE:PBYI). In a research note issued to the investors, the brokerage major Lowers the price-target to $60.00 per share. The shares have been rated Buy. The rating by UBS was issued on Apr 11, 2016.

In a different note, On Mar 29, 2016, RBC Capital said it Downgrades its rating on Puma Biotechnology Inc. In the research note, the firm Lowers the price-target to $103.00 per share. The shares have been rated ‘Sector Perform’ by the firm. On Mar 29, 2016, Credit Suisse said it Maintains its rating on Puma Biotechnology Inc. In the research note, the firm Lowers the price-target to $69.00 per share. The shares have been rated ‘Outperform’ by the firm. On Mar 29, 2016, JP Morgan said it Maintains its rating on Puma Biotechnology Inc. In the research note, the firm Lowers the price-target to $105.00 per share. The shares have been rated ‘Overweight’ by the firm. On Mar 29, 2016, Citigroup said it Maintains its rating on Puma Biotechnology Inc. In the research note, the firm Lowers the price-target to $90.00 per share. The shares have been rated ‘Buy’ by the firm. Credit Suisse said it Initiates Coverage on Puma Biotechnology Inc, according to a research note issued on Feb 11, 2016. The shares have been rated ‘Outperform’ by the firm. Credit Suisse said it Initiates Coverage on Puma Biotechnology Inc, according to a research note issued on Jan 20, 2016. In the research note, the firm Announces the price-target to $69 per share. The shares have been rated ‘Outperform’ by the firm.

Puma Biotechnology Inc (PBYI) shares turned negative on Fridays trading session with the shares closing down -0.1 points or -0.31% at a volume of 3,52,392. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $32.22. The peak price level was also seen at $32.22 while the days lowest was $31.08. Finally the shares closed at $31.85. The 52-week high of the shares is $244.9 while the 52-week low is $25.2. According to the latest information available, the market cap of the company is $1,035 M.

Puma Biotechnology Inc(PBYI) last announced its earnings results on Feb 29, 2016 for Fiscal Year 2015 and Q4.Earnings per share were $-1.90. Analysts had estimated an EPS of $-2.03.

Several Insider Transactions has been reported to the SEC. On Jul 8, 2015, Richard Paul Bryce (SR VP, CLINICAL RESEARCH & DEV) sold 3,000 shares at $110.03 per share price.

Puma Biotechnology Inc. is a biopharmaceutical company that focuses on the acquisition development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive breast cancer and patients with non-small cell lung cancer breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors HER1 HER2 and HER4.

Leave a Reply

Puma Biotechnology Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Puma Biotechnology Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.